Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Notebook: Sanofi, AstraZeneca Seek New Uses For Old R&D Sites

Executive Summary

VCs address the need for new capital at the U.K’s BioTrinity partnering and investor meeting; France and Germany move to work together on translational drug research; and France’s suspension of Bayer’s Diane 35 shows its tougher regulatory line.


Related Content

Deal Watch: Infinity Scores With AbbVie Deal, AbbVie Tries New Angle With Calico
Mixing Business And Philanthropy Yields Returns For Glaxo In Africa
Sanofi May Get EU Double Whammy After French Fine For Hindering Entry Of Plavix Generics
AstraZeneca’s R&D Restructuring Follows Hot Spot Trend
Better Late Than Never, J&J’s Innovation Centers Start Opening For Business
France Suspends Bayer Diane 35: Post-Mediator Strictness Or Prelude To Broad Withdrawal?
Sanofi Pulls Back On French Layoff Plans After Government Pressure
Merck KGAA Begins Transformation Effort By Closing Geneva Site
J&J Doubles Down On Orthopedics With Synthes Deal; Takes Lead In Trauma
For Pfizer Chief, The First Order Of Business Is Research


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts